공지 • Mar 30
Cronos Group Inc., Annual General Meeting, Jun 18, 2026 Cronos Group Inc., Annual General Meeting, Jun 18, 2026. Recent Insider Transactions Derivative • Mar 12
President exercised options and sold CA$451k worth of stock On the 8th of March, Michael Gorenstein exercised options to acquire 129k shares at no cost and sold these for an average price of CA$3.50 per share. This trade did not impact their existing holding. For the year to December 2019, Michael's total compensation was 19% salary and 81% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Michael's direct individual holding has increased from 12.51m shares to 12.81m. Company insiders have collectively sold CA$4.7m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Feb 27
Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2025 results: US$0.02 loss per share (down from US$0.11 profit in FY 2024). Revenue: US$146.6m (up 25% from FY 2024). Net loss: US$9.45m (down 123% from profit in FY 2024). Revenue exceeded analyst estimates by 5.1%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Price Target Changed • Feb 24
Price target increased by 7.2% to CA$4.24 Up from CA$3.95, the current price target is an average from 4 analysts. New target price is 13% above last closing price of CA$3.74. Stock is up 39% over the past year. The company is forecast to post a net loss per share of US$0.0034 compared to earnings per share of US$0.11 last year. 공지 • Feb 17
Cronos Group Inc. Launches New All-In-One Vape, Spinach PUFFERZ Cronos Group Inc. announced the launch of its newest all-in-one (AIO) vape, Spinach PUFFERZ. The latest innovation under Cronos' Spinach®? brand brings together high-quality cannabis infused with liquid diamonds in a convenient all-in-one device. Crafted for modern cannabis consumers who value functionality and design, Spinach PUFFERZ™? offers a seamless way to enjoy high-quality cannabis vape extracts and bold flavors. Every design element was carefully considered to deliver a differentiated experience. Spinach PUafferZ™? is Cronos' first AIO vape featuring the increasingly popular palm-style hardware. The device boasts a uniquely satisfying squish grip with a puffy exterior, a dual ceramic coil for maximum flavor and smooth draws, a boost button for temperature control, and a battery meter to indicate when a charge is needed. Spinach PUFFERZ™, the. 공지 • Feb 03
Cronos Group Launches Premium Lord Jones Brand in Israel, Advancing Borderless Product Strategy Cronos Group Inc. announced the launch of its Lord Jones premium cannabis brand in Israel. The introduction marks a significant milestone in Cronos' borderless product strategy, expanding the Company's globally recognized brand portfolio into one of the most advanced and discerning medical cannabis markets in the world. The first phase of the launch brings five premium indoor-grown flower strains to Israeli patients. Lord Jones, established in North America for its refined brand identity and elevated craftsmanship, now enters the Israeli medical market with a focus on meeting the needs of medical patients. The brand's expansion into Israel underscores Cronos' commitment to thoughtful international growth driven by disciplined execution and differentiated brand experiences. In addition to the core flower offering, Cronos plans to expand the Lord Jones brand in Israel with future special edition and limited-run products. Lord Jones products are now available in pharmacies across Israel. Major Estimate Revision • Jan 16
Consensus EPS estimates fall from profit to US$0.005 loss The consensus outlook for fiscal year 2025 has been updated. Expected to report loss instead of -US$0.005 instead of US$0.0205 per share profit previously forecast. Revenue forecast unchanged at US$137.9m Pharmaceuticals industry in Canada expected to see average net income growth of 40% next year. Consensus price target up from CA$3.95 to CA$4.10. Share price fell 5.4% to CA$3.53 over the past week. Recent Insider Transactions Derivative • Dec 17
President exercised options and sold CA$293k worth of stock On the 13th of December, Michael Gorenstein exercised options to acquire 65k shares at no cost and sold these for an average price of CA$4.51 per share. This trade did not impact their existing holding. For the year to December 2018, Michael's total compensation was 19% salary and 81% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Michael has owned 12.51m shares directly. Company insiders have collectively sold CA$4.5m more than they bought, via options and on-market transactions in the last 12 months. Valuation Update With 7 Day Price Move • Dec 12
Investor sentiment improves as stock rises 29% After last week's 29% share price gain to CA$4.48, the stock trades at a forward P/E ratio of 50x. Average trailing P/E is 14x in the Pharmaceuticals industry in Canada. Total returns to shareholders of 15% over the past three years. 공지 • Dec 10
Cronos Group Inc. (TSX:CRON) entered into a definitive share sale and purchase agreement to acquire CanAdelaar B.V. from Ring International Holding AG and Landewyck Tobacco S.A. Cronos Group Inc. (TSX:CRON) entered into a definitive share sale and purchase agreement to acquire CanAdelaar B.V. from Ring International Holding AG and Landewyck Tobacco S.A. on December 9, 2025. The total consideration for the transaction is structured as follows: The base amount is €57.5 million. This amount will be adjusted by the net indebtedness, where a positive cash balance will increase the total, and a negative sum will decrease it. Additionally, €0.13 million, referred to as the "Sellers W&I Premium Amount," will be subtracted. Furthermore, 50% of any additional underwriting fees incurred by the purchaser up to completion, specifically related to additional due diligence aimed at lifting certain exclusions currently included in the W&I Policy, will be added to the total consideration. The consideration includes an additional contingent payment, payable in cash, based on 0.5 times CanAdelaar’s normalized EBITDA for the years 2026 and 2027.
For the period ending September 30, 2025, CanAdelaar B.V. reported total revenue of €40.34 million and EBITDA of €24.05 million.
The transaction is subject to approval by regulatory board / committee and approval of offer by acquirer board. The deal has been unanimously approved by the board. The expected completion of the transaction is January 1, 2026 to June 30, 2026. 공지 • Nov 25
Cronos Group Inc. Launches Premium Lord Jones Live Resin Fusions in Canada Cronos Group Inc. announced is expanding its portfolio for its Lord Jones®? brand with new innovations designed to enhance its lineup of premium cannabis products in the Canadian market. The new Lord Jones Live Resin Fusions™? pre-rolls combine top-tier craftsmanship with exceptional cannabis genetics, reflecting the brand's continued dedication to quality and refinement. The Lord Jones Live Resin Fusion™? are carefully curated, pairing single-sourced dried flower with complementary, terpene-rich pure live resin caviar to deliver a delicious, flavor-forward, and differentiated smoking experience. Designed with an optimal ratio of live resin caviar-to-flower, each 0.5g pre-roll ensures a consistently smooth burn and high potency of 42%+ THC. Every pre-roll is fitted with a reusable ceramic tip, which cools the smoke for an even smoother, elevated experience. The Lord Jones Live Res in Fusions are now available in the following new strains: Lord Jones Live Resin F Fusion™? Durban Kush x Citrus Sap; Lord Jones Live Resin F intr™? Hell Fire OG x Cali Gas; Lord Jones Live ResinFusions™? Sour Diesel X Orange Velvet. New Lord Jones Live Resin F infusion™? are now available at select retailers across Canada. Reported Earnings • Nov 06
Third quarter 2025 earnings released: EPS: US$0.07 (vs US$0.022 in 3Q 2024) Third quarter 2025 results: EPS: US$0.07 (up from US$0.022 in 3Q 2024). Revenue: US$36.3m (up 6.1% from 3Q 2024). Net income: US$26.0m (up 211% from 3Q 2024). Profit margin: 71% (up from 24% in 3Q 2024). Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. 공지 • Oct 28
Cronos Group Inc. Brings Back Popular, Limited-Edition Spinach Green Apple-Flavored Products for the Fall Season Cronos Group Inc. announced that it is welcoming back its limited-edition Caramel Green Apple flavor to its best-selling lineup of SOURZ by Spinach edibles for the fall and Halloween season. The return of this popular and limited-edition product, which features buttery, sweet caramel and tart-green apple flavors and is perfect for the autumn months, follows its successful launch in Fall 2024. In addition to bringing back the original SOURZ by Spinach Caramel Green Apple 5-pack of gummies, Cronos is expanding its Fall season exclusive offerings with two new products: SOURZ by Spinach Fully Blasted Caramel Green Apple 10mg THC gummy; Spinach Sweet Green Apple 1g vape (Sativa): Infused with liquid diamonds and featuring crisp green apple flavor notes. These limited-time, seasonal Spinach products are available now across Canada. 공지 • Oct 09
Cronos Group Inc. Launches Sourz by Spinach Fully Blasted Multipacks Cronos Group Inc. announced that its popular SOURZ by Spinach Fully Blasted gummies will now be available in new multipack formats. The SOURZ by Spinach fully Blasted Multipacks with liquid diamond-infused gummies are now available in five of its most popular flavors, offering consumers more choice, convenience, and value when purchasing Canada's favorite cannabis edible. SOURZ by Spinach Fully Blasted Multipacks with Liquid diamond-infused gummies will be available in 5- and 10-packs in the following flavors: 10-Pack (10 x 10mg THC gummies): SOURZ by Spinach Fully Blasted Blue Raspberry Watermelon gummies; SOURZ by Spinach Fully Blasted Pink Lemonade gummies; SOUR Z by Spinach FullyBlasted Strawberry Mango gummies: SOURZ by spinach Fully Blasted Peach Orange gummies; 5-Pack (5 x 10mg THC gummies); SOURZ by Spinach- Fully Blasted Blue Raspberry Water Watermelon gummies; SourZ by Spinach fully Blasted Pink Lemonade gibles; SOURZ by SpinACH Fully Blasted Strawberry Mango gummies; SOURZ By Spinach Fully Blasting Peach Orange gummies; 5 -Pack (5 x 10mgTH gummies); SOURZ By Spinach Fully Blasting Peach Orange Gummies; 5-Pack (5 x 10mg THC gummies; SOURZby Spinach Fully Blast Blue Raspberry Watermelon gummies and SOURZ by Spinach? Fully Blasted Pink Lemonades gummies. The SOURZ by spinach Fully Blasted Multipack with liquid diamond-infused Gummies are available now in Alberta, British Columbia, Manitoba, Newfoundland, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan. Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CA$4.13, the stock trades at a forward P/E ratio of 109x. Average trailing P/E is 34x in the Pharmaceuticals industry in Canada. Total returns to shareholders of 3.0% over the past three years. Price Target Changed • Sep 03
Price target increased by 10% to CA$3.95 Up from CA$3.59, the current price target is an average from 2 analysts. New target price is 14% above last closing price of CA$3.48. Stock is up 17% over the past year. The company is forecast to post a net loss per share of US$0.015 compared to earnings per share of US$0.11 last year. Reported Earnings • Aug 08
Second quarter 2025 earnings: EPS misses analyst expectations Second quarter 2025 results: US$0.10 loss per share (further deteriorated from US$0.023 loss in 2Q 2024). Revenue: US$33.5m (up 21% from 2Q 2024). Net loss: US$39.7m (loss widened 354% from 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. 공지 • Aug 07
Cronos Group Inc. Appoints Lloyd Wilson as the Principal Accounting Officer, Effective as of August 7, 2025 Cronos Group Inc. Appointed Lloyd Wilson, Vice President, Controller, as the Company’s principal accounting officer, effective as of August 7, 2025. Lloyd is a seasoned financial leader and licensed Chartered Public Accountant with over 20 years of experience in financial reporting, internal audit, plant controllership, and operational finance. With a strong background in consumer-packaged goods and previous experience as a plant controller, Lloyd most recently served as a Corporate Controller, where he oversaw financial reporting, internal controls, and policy implementation. Price Target Changed • Jul 09
Price target increased by 14% to CA$4.08 Up from CA$3.59, the current price target is an average from 3 analysts. New target price is 43% above last closing price of CA$2.85. Stock is down 9.2% over the past year. The company is forecast to post a net loss per share of US$0.061 compared to earnings per share of US$0.11 last year. Major Estimate Revision • Jul 02
Consensus EPS estimates fall by 254%, revenue upgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$146.6m to US$149.5m. Forecast EPS reduced from -US$0.017 to -US$0.061 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 34% next year. Consensus price target of CA$3.77 unchanged from last update. Share price was steady at CA$2.61 over the past week. Major Estimate Revision • May 15
Consensus EPS estimates have been downgraded. The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$149.2m to US$145.5m. Now expected to report a loss of US$0.006 per share instead of US$0.0074 per share profit previously forecast. Pharmaceuticals industry in Canada expected to see average net income growth of 38% next year. Consensus price target of CA$3.48 unchanged from last update. Share price rose 5.0% to CA$2.92 over the past week. Reported Earnings • May 09
First quarter 2025 earnings: EPS and revenues exceed analyst expectations First quarter 2025 results: EPS: US$0.02 (up from US$0.006 loss in 1Q 2024). Revenue: US$32.3m (up 28% from 1Q 2024). Net income: US$6.12m (up US$8.36m from 1Q 2024). Profit margin: 19% (up from net loss in 1Q 2024). Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. 공지 • May 09
Cronos Group Inc. (TSX:CRON) announces an Equity Buyback for 19,270,951 shares, representing 5% for $50 million. Cronos Group Inc. (TSX:CRON) announces a share repurchase program. Under the program, the company will repurchase up to 19,270,951 shares representing 5% of it's issued share for $50 million. The repurchases will be made from available funds. The repurchase program is valid till May 13, 2026. 공지 • Apr 23
Cronos Group Inc. Unveils New Spinach 1.2g Vapes and SOURZ by Spinach Gummies Enhanced with Rare Cannabinoids Cronos Group Inc.'s best-selling cannabis brand, Spinach®?, introduced three all-new 1.2g vape products, each expertly crafted with premium THC and enhanced with rare cannabinoids for a uniquely elevated experience. Along with these innovative vape offerings, Cronos is also unveiling new SOURZ by Spinach®? Fully Blasted flavors, infused with rare cannabinoids. The new lineup includes three new 1.2 gram vapes in the following formats: Mango Kiwi Haze CBC (Sativa): A refreshing, uplifting blend with a 1:10 CBC-to-THC ratio. Peach Passionfruit Kush CBN (Indica): A dreamy, restful experience with a 1:10 CBN-to-THC ratio; Strawberry Watermelon OG CBG (Hybrid): A blissful, relaxed high with a 1:10 CBG-to-THC ratio.; Designed for consumers who prioritize both potency and added value, these vapes deliver 1,000mg of THC without compromising on the unique benefits of rare cannabinoids. Each product features winterized, distilled cannabis extract for purity, combined with terpene-rich flavors inspired by renowned cultivars. All Spinach®? vapes are crafted with ceramic heaters, stainless steel components, and food-grade materials to ensure quality and a smooth experience. In addition to the Spinach®? vape launch, Cronos is expanding its best-selling edible line, SOURZ by Spinach™?, with the new Fully Blasted lineup with each package containing one 10mg THC gummy in bold, fruit-forward flavors: Mango Lime: Tropical mango and tangy lime flavors with 10mg CBC and 10mg THC per gummy. 공지 • Mar 28
Cronos Group Inc., Annual General Meeting, Jun 20, 2025 Cronos Group Inc., Annual General Meeting, Jun 20, 2025. Recent Insider Transactions Derivative • Mar 26
President exercised options and sold CA$3.1m worth of stock On the 21st of March, Michael Gorenstein exercised options to acquire 1m shares at no cost and sold these for an average price of CA$2.61 per share. This trade did not impact their existing holding. For the year to December 2018, Michael's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Michael's direct individual holding has increased from 11.09m shares to 11.68m. Company insiders have collectively sold CA$4.4m more than they bought, via options and on-market transactions in the last 12 months. 공지 • Mar 20
Cronos Group Inc. Announces Chief Financial Officer Changes Cronos Group Inc. announced the appointment of Anna Shlimak as Chief Financial Officer, effective March 19, 2025. Ms. Shlimak, who previously served as Cronos’ Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition. Ms. Shlimak has been an integral part of Cronos’ leadership team for the last seven years, playing a key role in shaping the Company’s strategy, operational efficiencies, and engagement with the financial and investment community. During her tenure, she has led many strategic initiatives including cost optimization, revenue growth, and building Cronos’ corporate brand, which have positioned the Company for long-term success. Anna recently served as the Company’s Chief Strategy Officer and was responsible for managing and directing the organization’s corporate strategy, investor relations, communications, government affairs, and information systems departments. Prior to joining Cronos, Anna was the Head of Investor Relations at Quest Partners LLC, a research-driven alternative investment firm. Anna was responsible for business development, investor reporting, marketing, and communication initiatives for the fund. Before that, Anna held a range of roles at the New York Stock Exchange in both the New York and London offices. She received a Master of Business Administration from Columbia Business School and holds a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania. Recent Insider Transactions Derivative • Mar 19
President exercised options and sold CA$306k worth of stock On the 15th of March, Michael Gorenstein exercised options to acquire 112k shares at no cost and sold these for an average price of CA$2.72 per share. This trade did not impact their existing holding. For the year to December 2018, Michael's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Michael's direct individual holding has decreased from 11.09m shares to 10.45m. Company insiders have collectively sold CA$1.3m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Mar 12
President exercised options and sold CA$230k worth of stock On the 8th of March, Michael Gorenstein exercised options to acquire 80k shares at no cost and sold these for an average price of CA$2.86 per share. This trade did not impact their existing holding. For the year to December 2018, Michael's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Michael's direct individual holding has decreased from 11.09m shares to 10.20m. Company insiders have collectively sold CA$1.2m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Feb 28
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2024 results: EPS: US$0.11 (up from US$0.18 loss in FY 2023). Revenue: US$117.6m (up 35% from FY 2023). Net income: US$41.1m (up US$110.9m from FY 2023). Profit margin: 35% (up from net loss in FY 2023). Revenue missed analyst estimates by 2.0%. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Recent Insider Transactions Derivative • Dec 17
President exercised options and sold CA$183k worth of stock On the 13th of December, Michael Gorenstein exercised options to acquire 66k shares at no cost and sold these for an average price of CA$2.79 per share. This trade did not impact their existing holding. For the year to December 2017, Michael's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Michael has owned 11.09m shares directly. Company insiders have collectively sold CA$826k more than they bought, via options and on-market transactions in the last 12 months. Breakeven Date Change • Dec 05
Forecast to breakeven in 2025 The 3 analysts covering Cronos Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 82% to 2024. The company is expected to make a profit of US$10.2m in 2025. Average annual earnings growth of 95% is required to achieve expected profit on schedule. Reported Earnings • Nov 14
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: EPS: US$0.02 (up from US$0.004 loss in 3Q 2023). Revenue: US$34.3m (up 38% from 3Q 2023). Net income: US$8.35m (up US$9.81m from 3Q 2023). Profit margin: 24% (up from net loss in 3Q 2023). Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Major Estimate Revision • Nov 13
Consensus revenue estimates increase by 12%, EPS downgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from US$107.8m to US$120.7m. EPS estimate fell from -US$0.072 to -US$0.086 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 51% next year. Consensus price target of CA$3.44 unchanged from last update. Share price was steady at CA$3.15 over the past week. Major Estimate Revision • Oct 01
Consensus EPS estimates upgraded to US$0.074 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.083 to -US$0.074 per share. Revenue forecast unchanged from US$111.3m at last update. Pharmaceuticals industry in Canada expected to see average net income growth of 55% next year. Consensus price target of CA$3.51 unchanged from last update. Share price was steady at CA$2.87 over the past week. 공지 • Aug 28
Cronos Group Inc. Announces Lord Jones Live Resin Vapes and Ice Water Hash Pre-Rolls Now Available Across Canada Cronos Group Inc. is expanding its portfolio for its Lord Jones brand with new innovations to bolster its lineup of premium cannabis products in the Canadian market. The additions include new cultivars for the Lord Jones Ice Water Hash Fusions Pre-Rolls and Live Resin Vapes, which are now available across Canada. The Lord Jones Ice Water Hash Fusions Pre-Rolls and Live Resin Vapes are now available in the following new flavors and sizes: Lord Jones Ice Water Hash Fusions Pre-Rolls: Sour Blueberry x Sour Blueberry. 1g ice water hash flower pre-roll with blueberry and gas flavor notes. Indica | THC: 35-41% | 1x1g. Snow Lotus x Animal Mints. 1g ice water hash flower pre-roll with sweet, minty, and spicy flavor notes. Hybrid | THC: 35-41% | 1x1g Lord Jones Live Resin Vapes (All-in-One and 510-Cartridge): Gorilla Z Live Resin Vape A flavor-forward vape designed to boast an promoted berry, cherry, and grape flavor experience. Hybrid | 70+% THC . Available in two hardware options that are optimized for live resin usage: A sleek 0.5g all-in-one device. A high-quality 1g 510-thread cartridge. Breakeven Date Change • Aug 12
No longer forecast to breakeven The 7 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.46m in 2025. New consensus forecast suggests the company will make a loss of US$6.32m in 2026. Reported Earnings • Aug 09
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2024 results: US$0.02 loss per share (further deteriorated from US$0.015 loss in 2Q 2023). Revenue: US$27.8m (up 46% from 2Q 2023). Net loss: US$8.76m (loss widened 59% from 2Q 2023). Revenue exceeded analyst estimates by 7.2%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Major Estimate Revision • Jul 12
Consensus EPS estimates fall by 10% The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.042 to -US$0.046 per share. Revenue forecast unchanged at US$103.7m. Pharmaceuticals industry in Canada expected to see average net income growth of 54% next year. Consensus price target of CA$3.61 unchanged from last update. Share price rose 6.5% to CA$3.26 over the past week. Breakeven Date Change • Jul 11
No longer forecast to breakeven The 7 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.69m in 2025. New consensus forecast suggests the company will make a loss of US$6.12m in 2026. Major Estimate Revision • Jul 01
Consensus EPS estimates fall by 93% The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.022 to -US$0.042 per share. Revenue forecast of US$103.3m unchanged since last update. Pharmaceuticals industry in Canada expected to see average net income growth of 56% next year. Consensus price target down from CA$3.74 to CA$3.61. Share price was steady at CA$3.19 over the past week. 공지 • Jun 28
Cronos Group Inc. Brand Spinach®? Celebrates Summer with New Launches Cronos Group Inc.'s Spinach®? brand is expanding its portfolio of award-winning and best-selling cannabis products just in time for the summer months. Summer innovations feature new flavors and formats from Cronos' SOURZ by Spinach®? edibles and a premier milled flower product. The new SOURZ by Spinach™? Fully Blasted gummies offer the same great-tasting SOURZ by Spinach ®? flavors, now with 10 mg of THC per piece. The SOURZ by SpinACH®? Tropical Party Pack introduces new gummies with bolder tropical flavors, in the distinctive Spinach®? "S" shape. These gummies have a perfect blend of sour and sweet and utilize Cronos' proprietary flavor-masking technology. SOURZ by SpinachTM Fully Blasted includes one 10 mg THC gummy per package in the following flavors: Pink Lemonade; Sweet and refreshing flavors of raspberry and lemonade; Blue Raspberry Watermelon; Electric blue raspberry and refreshing watermelon; Cherry Lime; Delightful cherry and tangy lime. SOURZ by SpinACH™? Tropical Party Pack: 1 mg THC per gummy, 10 mg THC per pack; Featuring three new dual-flavors: Peach Passionfruit, Pineapple Coconut, and Strawberry Guava. Additionally, the Spinach®? brand will introduce Spinach®?, milled flower options designed to be ready to use for joints or vaporizers. Ready-to-use milled flower offerings have grown in popularity in the Canadian cannabis market, appealing to value-conscious consumers seeking convenience. Spinach Grindz™? caters to this growing demand by providing high-quality, milled cannabis that saves time and effort, allowing consumers to enjoy a consistent and hassle-free cannabis experience. Spinach Grindz®? are now available in the following strains: Citrus Crush; Milled flower with citrus, sour, and earthy notes; Cookie Dough; Milled flower with sweet, nutty, and creamy notes. 공지 • Jun 22
Cronos Group Inc. Elects Murray Garnick as Director Cronos Group Inc. at its Annual Meeting of Shareholders held on June 20, 2024, approved to elect Murray Garnick as director. Breakeven Date Change • May 12
Forecast breakeven date moved forward to 2025 The 8 analysts covering Cronos Group previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 87% to 2024. The company is expected to make a profit of US$5.67m in 2025. Average annual earnings growth of 62% is required to achieve expected profit on schedule. Reported Earnings • May 10
First quarter 2024 earnings: EPS and revenues exceed analyst expectations First quarter 2024 results: US$0.01 loss per share (improved from US$0.05 loss in 1Q 2023). Revenue: US$25.3m (up 26% from 1Q 2023). Net loss: US$2.24m (loss narrowed 88% from 1Q 2023). Revenue exceeded analyst estimates by 7.0%. Earnings per share (EPS) also surpassed analyst estimates by 1.9%. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Major Estimate Revision • May 07
Consensus EPS estimates upgraded to US$0.036 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.045 to -US$0.036 per share. Revenue forecast steady at US$99.8m. Pharmaceuticals industry in Canada expected to see average net income growth of 49% next year. Consensus price target of CA$3.57 unchanged from last update. Share price fell 10% to CA$3.63 over the past week. Breakeven Date Change • May 07
No longer forecast to breakeven The 7 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.72m in 2026. New consensus forecast suggests the company will make a loss of US$4.06m in 2026. Major Estimate Revision • Apr 16
Consensus EPS estimates fall by 24% The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.036 to -US$0.045 per share. Revenue forecast of US$100.9m unchanged since last update. Pharmaceuticals industry in Canada expected to see average net income growth of 50% next year. Consensus price target of CA$3.57 unchanged from last update. Share price fell 7.2% to CA$3.36 over the past week. 공지 • Mar 28
Cronos Group Inc., Annual General Meeting, Jun 20, 2024 Cronos Group Inc., Annual General Meeting, Jun 20, 2024. Major Estimate Revision • Mar 26
Consensus EPS estimates upgraded to US$0.037 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.046 to -US$0.037 per share. Revenue forecast steady at US$100.9m. Pharmaceuticals industry in Canada expected to see average net income growth of 56% next year. Consensus price target of CA$3.46 unchanged from last update. Share price rose 17% to CA$3.62 over the past week. 공지 • Mar 26
Cronos Group Inc. Launches Lord Jones Chocolate Fusions Cronos Group Inc. announced the launch of Lord Jones Chocolate Fusions, its exciting first entry into the chocolate edibles category. Cronos' newest edible innovation was developed and designed by an expert team of culinary chefs, food scientists, and leaders in cannabis product development. The bite-sized Chocolate Fusions feature a dynamic, multi- texture experience, combining a soft and chewy center, crunch inclusions, and an outer layer of rich creamy chocolate that delivers a decadent sweet treat for adult cannabis consumers. Lord Jones Chocolate Fusions feature winning attributes to attract cannabis consumers, including three delicious flavor combinations, an artisanal design that highlights a creative combination of textures, and a flavor-masking system to ensure outstanding taste. Through an extensive research and sensory testing process, team of experts seized the opportunity to deliver an exceptional edible that elevates the overall category. Each package of Lord Jones Chocolate Fusions includes five pieces with 2mg of THC per piece. Chocolate Fusions will be available in the following flavors and formats: Lord Jones Cookies & Cream Chocolate Fusions, 10mg THC total per package, Three layers of white chocolate, cookie crunch bits, and a chewy fudge center, Lord Jones Salted Caramel Crunch 1:1 CBD | THC Chocolate Fusions, 10mg CBD per package, 10mg THC and 10mg CBD per package, Three layers of milk chocolate, a sweet and salty crunch, and a smooth caramel center, Lord Jones Dazzleberry Pop Chocolate Fusions, 10mgTH total per package, Three layers the gold-dusted dark chocolate, a crackling pop, and a sweet berry center. Cronos continues to be an award-winning leader in cannabis edibles. The same team behind the hugely popular SOURZ by Spinach® and Spinach FEELZTM portfolio of gummies leveraged their expertise in the edibles space to create this innovation for the chocolate category for the Lord Jones® brand. Recent Insider Transactions Derivative • Mar 20
President exercised options and sold CA$232k worth of stock On the 15th of March, Michael Gorenstein exercised options to acquire 87k shares at no cost and sold these for an average price of CA$2.68 per share. This trade did not impact their existing holding. For the year to December 2017, Michael's total compensation was 4% salary and 96% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Michael's direct individual holding has increased from 9.64m shares to 9.83m. Company insiders have collectively sold CA$963k more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Mar 03
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: US$0.18 loss per share (improved from US$0.45 loss in FY 2022). Revenue: US$87.2m (down 5.1% from FY 2022). Net loss: US$69.8m (loss narrowed 59% from FY 2022). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 101%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. Major Estimate Revision • Mar 02
Consensus EPS estimates fall by 44% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$109.2m to US$102.2m. Losses expected to increase from US$0.03 per share to US$0.043. Pharmaceuticals industry in Canada expected to see average net income growth of 63% next year. Consensus price target of CA$3.49 unchanged from last update. Share price fell 9.2% to CA$2.75 over the past week. Breakeven Date Change • Dec 31
Forecast to breakeven in 2026 The 8 analysts covering Cronos Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$236.3k in 2026. Average annual earnings growth of 68% is required to achieve expected profit on schedule. Recent Insider Transactions Derivative • Dec 17
President exercised options and sold CA$169k worth of stock On the 13th of December, Michael Gorenstein exercised options to acquire 66k shares at no cost and sold these for an average price of CA$2.58 per share. This trade did not impact their existing holding. For the year to December 2016, Michael's total compensation was 4% salary and 96% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Michael's direct individual holding has increased from 9.64m shares to 10.65m. Company insiders have collectively sold CA$545k more than they bought, via options and on-market transactions in the last 12 months. 공지 • Dec 15
Cronos Group Inc. Announces Launch of Its Highly Anticipated Lord Jones Live Resin Vapes in Two Different Hardware Options Cronos Group Inc. announced the launch of its highly anticipated Lord Jones Live Resin Vapes in two different hardware options. Crafted with the discerning cannabis consumer in mind, these products embody a commitment to excellence, offering an unmatched combination of curated strains, pure live resin, and elegant high-quality hardware. The live resin format offers consumers a multi-dimensional, true-to-plant experience. This format is well suited for discerning consumers looking to level-up their cannabis experience. These vapes feature consistent high potency, with THC levels exceeding 70%, and advanced hardware designed to optimize live resin consumption, preserving terpenes and preventing clogging. The lineup also features versatile sizing options, including a 0.5g trial size in the convenience of an all-in-one device and a 1g stock-up size as a 510-thread cartridge, catering to both enthusiasts and those new to the category. Lord Jones Live Resin Vape are available in the following formats: Lord Jones Purple Lemon Haze Live Resin Vapes; Designed to deliver a supremely elevated experience, with notes of zesty citrus, pleasant earthiness, and sharp and spicy pepper flavors; Sativa | THC: 72-78% Available in two hardware options that have been optimized for live resin usage: A unique sleek 0.5g all-in-one device; A high-quality 1g 510-thread cartridge; Lord Jones Deadhead OG Live Resin Vapes; designed to deliver a truly complex flavor experience with savory, spicy, and woody flavors; Indica | THC: 71-77% Available in two hardware options That have been optimized for live resin use: A unique sleek 0. 5g all-in-one devices will be available in Alberta, Manitoba, Ontario, Saskatchewan and Yukon in 2024. Lord Jones batteries will be available in Manitoba, Ontario, Saskatchewan andYukon by early 2024. Lord Jones batteries will been available in Manitoba, Ontario, Alberta, Ontario, Saskatchewan and YukON by early 2024. 공지 • Nov 29
Future Farmco Canada Inc. entered into an agreement to acquire Peace Naturals Project Inc. from Cronos Group Inc. (TSX:CRON) for CAD 23 million. Future Farmco Canada Inc. entered into an agreement to acquire Peace Naturals Project Inc. from Cronos Group Inc. (TSX:CRON) for CAD 23 million on November 26, 2023. The aggregate purchase price will be paid as CAD 0.1 million will be paid in trust within two business days of the date of the Sale Agreement (b) CAD 1 million will be paid in trust within five business days of the waiver or satisfactions of the Buyer’s Condition, the Seller’s Condition and the Lease Condition (each, as defined below) and (c) the balance of the aggregate purchase price will be paid at the closing. Closing is expected to occur on the first business day that falls 30 calendar days following the later of (i) the satisfaction or waiver of the Buyer’s Condition or (ii) the satisfaction or waiver of the Seller’s Condition. Breakeven Date Change • Nov 11
Forecast to breakeven in 2025 The 8 analysts covering Cronos Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 78% per year to 2024. The company is expected to make a profit of US$7.29m in 2025. Average annual earnings growth of 92% is required to achieve expected profit on schedule. Reported Earnings • Nov 10
Third quarter 2023 earnings released: US$0.005 loss per share (vs US$0.098 loss in 3Q 2022) Third quarter 2023 results: US$0.005 loss per share (improved from US$0.098 loss in 3Q 2022). Revenue: US$24.8m (up 19% from 3Q 2022). Net loss: US$1.46m (loss narrowed 96% from 3Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. 공지 • Nov 04
Cronos Group Inc. Launches Its Cannabis Brand Lord Jones in the Canadian Adult-Use Cannabis Market Cronos Group Inc. announced that it has launched its award-winning cannabis brand Lord Jones® in the Canadian adult-use cannabis market. The Lord Jones® brand will build on its legacy of delivering premium quality cannabis products by returning to its roots with bold THC-focused product innovations. The first Lord Jones® product to launch in Canada are Lord Jones® Hash Fusions pre-rolls. The popularity of hash products and premium pre-rolls is increasing amongst adult consumers. Hash is currently the most popular solventless infusion and is the second most popular infusion overall in the pre-roll category. The Lord Jones® Hash Fusions pre-rolls go beyond delivering an elevated, true-to-plant consumption experience. These pre-rolls are crafted with an optimized ratio of premium high-potency flower and complementary solventless ice water hash, which preserves the buds’ natural terpenes, fitted with a reusable ceramic tip to help cool the smoke. This new product has been extensively researched and sensory tested to deliver a smoother experience featuring bold cannabis flavors. Lord Jones® Hash Fusions pre-rolls are available in the following formats: Lord Jones® Hash Fusions – White Tahoe OG Flower x White Tahoe OG Ice Water Hash; Indica | THC: 35 – 40% | 1x1g; Lord Jones® Hash Fusions – Cosmic Kush Flower x Platinum GMO Ice Water Hash; Hybrid | THC: 35 – 40%+| 1x1g. 공지 • Oct 31
Cronos Group Inc. Unveils Its New THCV Products: Spinach FEELZ™? Full Tilt Cronos Group Inc. announced the launch of two new THCV-infused products; Spinach FEELZ Full Tilt THCV vape and gummy. Cronos also plans to launch a THCV-infused pre-roll under the Spinach FEELZ brand, which will add an additional offering under its robust and growing pre-roll portfolio. The Full Tilt THCV lineup is designed to give adult consumers an exciting new cannabis experience. The Spinach FEELZ full Tilt product range includes: Spinach FEELZ FullTilt Blue Razz Durban 7:1 THC|THCV vape; 700mg of THC and 100mg of THCV per 1g cartridge; Spinach FEELZ fullTilt Blue Raspberry Lemonade 1:2 THC|THCV gummies; 5 pieces/pack with 10mg of THC and 20mg THCV per pack. The THCV vape is now available in Alberta, British Columbia, and Ontario and the THCV edibles are available now in Ontario and British Columbia and will be available in Alberta by November 30. THC infused pre-rolls are planned for launch in 2024. Through Spinach FEELZ, Cronos is committed to bringing a full line of products featuring rare cannabinoids to consumers in a wide range of product formats. Each product is designed to deliver unique and enhanced experiences made possible through proprietary blends of rare cannabinoids alongside more well-known cannabinoids, like THC and CBD. Each product is formulated to help adult consumers, "Feelz. The Way You want." With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos' diverse international brand portfolio includes Spinach®?, PEACE NATURALS®? and Lord Jones®?. Major Estimate Revision • Aug 15
Consensus revenue estimates decrease by 14%, EPS upgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$95.4m to US$82.1m. EPS estimate increased from -US$0.127 to -US$0.118 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 5.9% next year. Consensus price target broadly unchanged at CA$3.37. Share price fell 6.0% to CA$2.33 over the past week. 공지 • Aug 10
Cronos Group Inc. Revises Earnings Guidance for the Full Year 2023 Cronos Group Inc. revised earnings guidance for the full year 2023. For the year, the company has decided to discontinue providing net revenue guidance and to withdraw previously announced net revenue target of $100 million to $110 million for full-year 2023. The discontinuance of providing net revenue guidance reflects turbulent market conditions beyond previous expectations in the markets in which Company operate, specifically, increasing political unrest and stagnant patient growth in Israel, the decision to exit the U.S. business, and competitive activity in Canada. In addition, foreign exchange rates have had unfavorable impact on Company's net revenue. Reported Earnings • Aug 08
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2023 results: US$0.013 loss per share (improved from US$0.054 loss in 2Q 2022). Revenue: US$19.0m (down 18% from 2Q 2022). Net loss: US$5.53m (loss narrowed 73% from 2Q 2022). Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 39%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 32% per year, which means it has not declined as severely as earnings. 공지 • Jul 07
Cronos Reportedly Explores Possible Sale After Attracting Takeover Interest Cronos Group Inc. (TSX:CRON), the Canadian cannabis producer backed by cigarette maker Altria Group Inc. (MO.N), is exploring options that include a potential sale after attracting acquisition interest, people familiar with the matter said. Toronto-based Cronos is working with a financial adviser to handle the expressions of interest in a deal from other companies, including U.S.-based peer Curaleaf Holdings Inc. (CURA.CD), the sources said. The sources requested anonymity because the discussions are confidential, and they cautioned that no transaction is certain. Cronos and Curaleaf declined to comment. Spokespeople for Altria did not immediately respond to a request for comment. 공지 • May 20
Cronos Group Inc. Announces Executive Changes On May 18, 2023, Cronos Group Inc. appointed James McGinness to the position of Vice President, Controller, which includes serving as the Company’s principal accounting officer, effective as of May 22, 2023. On May 18, 2023, the Company determined that Carlos Cortez, the Company’s Vice President, Controller, will no longer serve as the Company’s principal accounting officer as of May 22, 2023 and will separate from the Company, effective as of June 16, 2023. Prior to joining the Company, Mr. McGinness, age 45, was the Acting Chief Financial Officer and Vice President, Corporate Controller for MarketWise Inc. since April 2019. While at MarketWise, Mr. McGinness was responsible for the Accounting, Tax, External and Internal Financial Reporting, Investor Relations, and Financial Planning and Analysis functions and was instrumental in restructuring and developing a world-class finance organization while shepherding MarketWise through an Up-C SPAC transaction and several other strategic transactions. Prior to MarketWise, Mr. McGinness served as Corporate Controller at GSE Systems from August 2016 until November 2018 and previously held various management roles at Exelon, Washington Gas, T. Rowe Price and McCormick. Mr. McGinness is a CPA and earned a Bachelor of Science in Accounting from the State University of New York at Albany. Recent Insider Transactions Derivative • May 16
President exercised options and sold CA$63k worth of stock On the 11th of May, Michael Gorenstein exercised options to acquire 25k shares at no cost and sold these for an average price of CA$2.54 per share. This trade did not impact their existing holding. For the year to December 2016, Michael's total compensation was 4% salary and 96% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2022, Michael's direct individual holding has increased from 9.47m shares to 10.62m. Company insiders have collectively bought CA$557k more than they sold, via options and on-market transactions, in the last 12 months. Major Estimate Revision • May 16
Consensus EPS estimates upgraded to US$0.14 loss, revenue downgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$103.3m to US$99.7m. 2023 losses expected to reduce from -US$0.156 to -US$0.138 per share. Pharmaceuticals industry in Canada expected to see average net income decline 7.8% next year. Consensus price target down from CA$4.14 to CA$3.72. Share price fell 10% to CA$2.35 over the past week. Price Target Changed • May 15
Price target decreased by 8.6% to CA$3.78 Down from CA$4.14, the current price target is an average from 9 analysts. New target price is 63% above last closing price of CA$2.32. Stock is down 46% over the past year. The company is forecast to post a net loss per share of US$0.14 next year compared to a net loss per share of US$0.45 last year. 공지 • May 10
Cronos Group Inc. Provides Revenue Guidance for the Full Year 2023 Cronos Group Inc. Provided revenue guidance for the full year 2023. For the year, the company expected to be between $100 million to $110 million. Reported Earnings • May 10
First quarter 2023 earnings: EPS and revenues miss analyst expectations First quarter 2023 results: US$0.10 loss per share. Revenue: US$20.1m (down 20% from 1Q 2022). Net loss: US$19.2m (loss narrowed 41% from 1Q 2022). Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 19%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in Canada. Major Estimate Revision • Mar 07
Consensus revenue estimates decrease by 11%, EPS upgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$114.3m to US$101.4m. EPS estimate increased from -US$0.175 to -US$0.155 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 7.1% next year. Consensus price target down from CA$4.56 to CA$4.40. Share price fell 4.4% to CA$2.83 over the past week. Reported Earnings • Mar 01
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: US$0.45 loss per share (improved from US$1.07 loss in FY 2021). Revenue: US$91.9m (up 24% from FY 2021). Net loss: US$168.7m (loss narrowed 57% from FY 2021). Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) missed analyst estimates by 59%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance. Price Target Changed • Feb 16
Price target decreased by 11% to CA$4.58 Down from CA$5.14, the current price target is an average from 9 analysts. New target price is 44% above last closing price of CA$3.18. Stock is down 33% over the past year. The company is forecast to post a net loss per share of US$0.29 next year compared to a net loss per share of US$1.07 last year. Board Change • Jan 24
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Kendrick Ashton was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. 
